Optimal anatomic coverage for CT in staging lung cancer: Lessons from PET-CT correlation

Gross, Barry H.; Brown, Richard K.; Kalemkerian, Gregory P.

doi:10.1016/j.lungcan.2010.10.021

Cited by 7 publications

(3 citation statements)

References 23 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…51,52 Chest CT is a commonly used imaging modality for MLN staging in lung adenocarcinoma patients. 53,54 For the primary lung adenocarcinoma of Patient 1 (2D-LA-Mass Mapping signal 63.72 ± 7.24 fg in Figure 4C), CT imaging of the lung and mediastinal windows (Figure 5A,B) showed that the tumor is located in the right lower lobe of the right lung marked by a red dotted circle. We further observed the enlargement, calcification, fusion, and invasion of the vessel wall in the MLN of the lung from chest CT imaging.…”

Section: Resultsmentioning

confidence: 99%

“…The lymph node status of primary tumors is a paramount indicator for evaluating cancer invasion/metastasis . Mediastinal lymph node (MLN) metastasis is associated with the degree of malignancy and invasion/metastasis of lung adenocarcinoma. , Chest CT is a commonly used imaging modality for MLN staging in lung adenocarcinoma patients. , For the primary lung adenocarcinoma of Patient 1 (2D-LA-Mass Mapping signal 63.72 ± 7.24 fg in Figure C), CT imaging of the lung and mediastinal windows (Figure A,B) showed that the tumor is located in the right lower lobe of the right lung marked by a red dotted circle. We further observed the enlargement, calcification, fusion, and invasion of the vessel wall in the MLN of the lung from chest CT imaging.…”

Section: Results and Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Precise Diagnosis of Cancer Invasion/Metastasis via 2D Laser Ablation Mass Mapping of Metalloproteinase in Primary Cancer Tissue

et al. 2018

View full text Add to dashboard Cite

Cancer invasion and metastasis remain the major causes of over 90% of patient deaths. Molecular imaging methods such as computed tomography (CT)/magnetic resonance imaging (MRI) can precisely assess primary regional lymph node invasion and distant organ metastasis via body scanning; however, such diagnostic methods are often utilized too late for cancer therapy. To date, pathologic methods mainly provide information on differentiation/ proliferation and potential drug therapy biomarkers of primary tumors rather than precisely reveal tumor regional invasion and distant metastasis in the body. We hypothesized that quantification of membrane type-1 matrix metalloproteinase (MT1-MMP) levels in primary tumor tissue will provide a precise assessment of tumor regional lymph node invasion and remote organ metastasis. In this work, we developed peptide-coated Au clusters with intrinsic red fluorescence and a specific mass signal. When these clusters labeled MT1-MMP in tumor tissue sections derived from the xenograft lung carcinoma model, human lung carcinoma and human renal carcinoma, we could directly observe MT1-MMP via optical fluorescence microscopy and quantitatively detect the MT1-MMP expression level via laser ablation inductively coupled plasma mass spectrometry 2D mapping (2D-LA-Mass Mapping). By observing and quantifying the MT1-MMP expression level in primary human lung carcinoma and human renal carcinoma tissue sections, we precisely assessed the risk of primary tumor invasion/metastasis. Importantly, the accuracy of this pathologic method was verified by CT/MRI molecular imaging of cancer patients and traditional hematoxylin and eosin (H&E) staining/immunohistochemistry (IHC)/ immunofluorescence (IF) pathologic studies of primary tumor tissues.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Results and Discussionmentioning

confidence: 99%

The Precise Diagnosis of Cancer Invasion/Metastasis via 2D Laser Ablation Mass Mapping of Metalloproteinase in Primary Cancer Tissue

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Computed tomography (CT) with intravenous contrast is the preferred technique in the study of lung cancer [2,5], and it should include the entire thorax and upper abdomen. It is not necessary to cover a larger area of the abdomen, since it does not significantly increase the accuracy of staging [6]. Positron-emission tomography (PET) with the glucose analogue 18 F-FDG and especially, PET/CT with 18 F-FDG, have revolutionised the staging of lung cancer.…”

Section: Non-invasive Stagingmentioning

confidence: 99%

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer

et al. 2019

View full text Add to dashboard Cite

Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, potentially resectable and unresectable tumours. To improve the prognostic capacity of the TNM classification, it has been agreed to divide stage III into sub-stages IIIA, IIIB and IIIC that have very different 5-year survival rates (36, 26 and 13%, respectively). Currently, it is considered that both staging and optimal treatment of stage III NSCLC requires the joint work of a multidisciplinary team of expert physicians within the tumour committee. To improve the care of patients with stage III NSCLC, different scientific societies involved in the diagnosis and treatment of this disease have agreed to issue a series of recommendations that can contribute to homogenise the management of this disease, and ultimately to improve patient care.

show abstract

The Staging of Lung Cancer

Rice¹

2012

Diagnostic Pathology of Pleuropulmonary Neoplasia

View full text Add to dashboard Cite

Optimal anatomic coverage for CT in staging lung cancer: Lessons from PET-CT correlation

Cited by 7 publications

References 23 publications

The Precise Diagnosis of Cancer Invasion/Metastasis via 2D Laser Ablation Mass Mapping of Metalloproteinase in Primary Cancer Tissue

The Precise Diagnosis of Cancer Invasion/Metastasis via 2D Laser Ablation Mass Mapping of Metalloproteinase in Primary Cancer Tissue

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer

The Staging of Lung Cancer

Contact Info

Product

Resources

About